CLAL INSURANCE ENTERPRISE by CLAL INSURANCE ENTERPRISES HOLDINGS LTD. Stock (OTC: CIEHF)

Latest news for CLAL INSURANCE ENTERPRISE by CLAL INSURANCE ENTERPRISES HOLDINGS LTD. (OTC:CIEHF) Stock

CLAL INSURANCE ENTERPRISE by CLAL INSURANCE ENTERPRISES HOLDINGS LTD.

Truist analyst William Stein attended <a target="_blank" href="https://www.benzinga.com/topic/ces" rel="noreferrer noopener">CES 2025 this</a> past week and hosted several meetings with high-profile companies in the semiconductor sector.
The over-arching theme is that spending on AI infrastructure is firm, which benefits Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) as it penetrates the $35 billion client compute market, challenging Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) and Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>).
Demand for diversified end market semiconductors is mixed to weak, with ON Semiconductor Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) sounding particularly weak,<a href="https://www.benzinga.com/quote/on/analyst-ratings"> prompting an analyst downgrade</a>. Additionally, Stein increased his Analog Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) price target.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/25/01/42843417/nvidia-highlights-ai-chips-powering-pubg-robotics-chatgpt-moment-automotive-expansion-and-more-at-ces-event" rel="noreferrer noopener">Nvidia Highlights AI Chips Powering PUBG, Robotics &#8216;ChatGPT Moment,&#8217; Automotive Expansion And More At CES Event</a>
Stein noted Nvidia as the AI company, a sustainable leader in massively parallel and heterogeneous compute chips, software, and, lately, services to enable AI &amp; related applications. Nvidia&#8217;s leadership is steered more by its culture of innovation, an ecosystem of incumbency, and substantial investment in software, services, and base AI models, making its chips a default choice for most engineers building AI systems.
The analyst expects Nvidia&#8217;s superior gaming and server acceleration positioning and AI to support structural fundamental growth and stock outperformance. Stein noted that Analog Devices is capitalizing on sound organic investments and creating a better future with M&amp;A, including accelerating sales growth and improving expense efficiencies.
After a series of stumbles, Intel lost its leadership positions in semiconductor manufacturing process technology to Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) and CPU performance to AMD. 
The company recently established a clear goal to regain process and product leadership. Currently, and over the next few years, the company&#8217;s competitive position, margins, and cash flows have subsided.
On Semiconductor is in the middle to late innings of a significant transformation. The changes are rooted in shifting to an &#8220;IP-first&#8221; strategy from a &#8220;manufacturing-first&#8221; strategy. Unfortunately, the company is experiencing a substantial shortfall in demand that mutes Stein&#8217;s optimism in the near to medium term.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/42872581/microns-7-billion-bet-on-ai-driven-memory-singapore-facility-set-to-boost-innovation-and-jobs" target="_blank" rel="noreferrer noopener">Micron&#8217;s $7 Billion Bet on AI-Driven Memory In Singapore Facility Set to Boost Innovation</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

News

Downgrades

Analyst Ratings

Trading Ideas

INTC

NVDA

Nvidia's AI Leadership Shines While ON Semiconductor Faces Demand Slump: Analyst

Citigroup analyst Daniel Grosslight maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Buy and raises the price target from $31 to $35.

Price Target

Citigroup Maintains Buy on Phreesia, Raises Price Target to $35

Citigroup analyst Christopher Allen maintains Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Neutral and lowers the price target from $85 to $80.

SCHW

Citigroup Maintains Neutral on Charles Schwab, Lowers Price Target to $80

Rumors

OKUR

Watching OnKure Therapeutics; Shares See Volume As Traders Circulate Stock Moving In Sympathy With Eli Lilly's Acquisition Talks To Buy Scorpion Therapeutics; Co Developing A Mutant-Selective PI3Kα Inhibitor

RLAY

Relay Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Down -13.5%

JPMorgan shifted gears on <a href="https://www.benzinga.com/topic/mobility">air mobility stocks</a> Archer Aviation Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) and Joby Aviation Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>), downgrading them despite strong sector enthusiasm.
Analyst Bill Peterson adjusted Archer Aviation stock to a Neutral rating and Joby Aviation stock to Underweight, noting their significant market gains surged past what fundamentals justify.
<h1 class="wp-block-heading">Market Enthusiasm Outpaces Fundamentals</h1>
Peterson highlighted that Archer and Joby have outperformed the Clean Tech sector, gaining 145% and 86%, respectively, over the past six months. This rise correlates with speculative inflows and market movements aligned with Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Rocket Lab USA Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>). &#8220;These companies are trading as if regulatory hurdles have already been cleared,&#8221; Peterson stated, warning that elevated valuations could retreat as regulatory challenges persist.
Read Also: <a href="https://www.benzinga.com/tech/25/01/42905406/tesla-launches-refreshed-model-y-in-china-amid-rising-competition">Tesla Launches Refreshed Model Y In China Amid Rising Competition</a>
<h1 class="wp-block-heading">Certification Challenges Continue</h1>
Despite potential regulatory possibly easing under the upcoming Trump administration, ongoing safety testing and certification remain hurdles. Peterson sees <a href="https://www.benzinga.com/24/12/42464770/whats-going-on-with-archer-aviation-stock-today">Archer&#8217;s partnership with defense tech company Anduril</a> as promising but believes its immediate valuation upside is capped.
He assigned a $9 price target, reflecting incremental earnings potential from its defense ventures.
Similarly, while Joby&#8217;s leadership in for-credit testing and partnerships,<a href="https://www.benzinga.com/trading-ideas/movers/24/11/42169194/joby-gets-toyotas-500m-dollar-lift-evtol-pioneer-making-new-highs"> such as with </a><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42169194/joby-gets-toyotas-500m-dollar-lift-evtol-pioneer-making-new-highs">Toyota Motor Corp</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>), indicate future growth, Peterson remains cautious.
The raised price target of $6 still implies downside risk due to certification uncertainties and market volatility.
<h1 class="wp-block-heading">Balancing Growth Potential, Risks</h1>
Peterson anticipates potential capital raises to fund commercialization efforts for both companies. 
&#8220;Investors must tread carefully,&#8221; he warned, suggesting that high short interest could lead to rapid price declines despite operational progress. 
As Archer and Joby push toward commercialization, the analyst sees significant long-term potential but remains wary of near-term risks tied to market enthusiasm outpacing operational milestones.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/42909739/onvo-l60-delivers-big-for-nio-over-20000-vehicles-sold-in-first-100-days">Onvo L60 Delivers Big For Nio: Over 20,000 Vehicles Sold In First 100 Days</a></li>
</ul>
Photo: Courtesy Joby Aviation

Long Ideas

Tech

ACHR

JOBY

RKLB

TSLA

eVTOL Market Soars Too High? Analyst Gives Archer, Joby Downgrades

Relay Therapeutics Shares Resume Trade

CHSN

Chanson International Shares Resume Trade

<a href="https://www.ft.com/content/fdd081b7-4ae3-4160-a246-a0afe1b86df2" title="https://www.ft.com/content/fdd081b7-4ae3-4160-a246-a0afe1b86df2">https://www.ft.com/content/fdd081b7-4ae3-4160-a246-a0afe1b86df2</a>

"Eli Lilly In Advanced Talks To Buy U.S. Cancer Biotech For Up To $2.5B; Scorpion's Drug Candidate Inhibits A Mutation That Is A Major Driver Of Breast, Gynaecological And Head And Neck Cancers" - Financial Times

Whales with a lot of money to spend have taken a noticeably bullish stance on YPF.
Looking at options history for YPF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YPF#NYSE">YPF</a>) we detected 13 trades.
If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish expectations and 38% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $560,033 and 10, calls, for a total amount of $788,909.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $60.0 for YPF over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for YPF's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of YPF's whale trades within a strike price range from $30.0 to $60.0 in the last 30 days. 
<h3>YPF 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736534732_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>YPF</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$7.7</td>
<td>$7.6</td>
<td>$7.7</td>
<td>$48.00</td>
<td>$308.0K</td>
<td>100</td>
<td>235</td>
</tr>
<tr>
<td>YPF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.65</td>
<td>$1.65</td>
<td>$1.65</td>
<td>$45.00</td>
<td>$206.9K</td>
<td>7.7K</td>
<td>1.2K</td>
</tr>
<tr>
<td>YPF</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$7.8</td>
<td>$7.7</td>
<td>$7.7</td>
<td>$48.00</td>
<td>$180.9K</td>
<td>100</td>
<td>235</td>
</tr>
<tr>
<td>YPF</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.75</td>
<td>$1.5</td>
<td>$1.65</td>
<td>$45.00</td>
<td>$124.2K</td>
<td>7.7K</td>
<td>1.2K</td>
</tr>
<tr>
<td>YPF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$4.3</td>
<td>$4.2</td>
<td>$4.2</td>
<td>$55.00</td>
<td>$101.6K</td>
<td>648</td>
<td>250</td>
</tr>
</tbody>
</table>

<h3>About YPF</h3>
YPF SA is an Argentina-based integrated oil and gas company. It is engaged in operating a fully integrated oil and gas chain across the domestic upstream, downstream, and gas and power segments. The company's upstream operations consist of the exploration, development, and production of crude oil, natural gas, and LPG. Its downstream operations include the refining, marketing, transportation, and distribution of oil and a wide range of petroleum products, petroleum derivatives, petrochemicals, LPG, and bio-fuels. The company generates maximum revenue from the downstream segment.
After a thorough review of the options trading surrounding YPF, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>YPF's Current Market Status</h3>
<ul>
<li>With a trading volume of 2,182,876, the price of YPF is up by 0.66%, reaching $45.62.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 54 days from now.</li>
</ul>
<h3>What The Experts Say On YPF</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $59.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from JP Morgan has elevated its stance to Overweight, setting a new price target at $59. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest YPF options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

What the Options Market Tells Us About YPF

Investors with a lot of money to spend have taken a bullish stance on VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VFC, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 10 uncommon options trades for VF.
This isn't normal.
The overall sentiment of these big-money traders is split between 70% bullish and 30%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $117,275, and 7 are calls, for a total amount of $446,341.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $10.0 and $25.0 for VF, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for VF options trades today is 11987.14 with a total volume of 26,411.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for VF's big money trades within a strike price range of $10.0 to $25.0 over the last 30 days.
<h3>VF Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736534728_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VFC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.1</td>
<td>$1.07</td>
<td>$1.11</td>
<td>$22.50</td>
<td>$163.1K</td>
<td>35.3K</td>
<td>7.9K</td>
</tr>
<tr>
<td>VFC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.85</td>
<td>$2.85</td>
<td>$2.85</td>
<td>$20.00</td>
<td>$91.2K</td>
<td>23.1K</td>
<td>373</td>
</tr>
<tr>
<td>VFC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.45</td>
<td>$5.8</td>
<td>$6.35</td>
<td>$20.00</td>
<td>$63.5K</td>
<td>3.5K</td>
<td>101</td>
</tr>
<tr>
<td>VFC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$0.55</td>
<td>$0.47</td>
<td>$0.55</td>
<td>$21.00</td>
<td>$49.2K</td>
<td>1.4K</td>
<td>1.1K</td>
</tr>
<tr>
<td>VFC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$3.55</td>
<td>$3.45</td>
<td>$3.55</td>
<td>$22.50</td>
<td>$42.2K</td>
<td>76</td>
<td>120</td>
</tr>
</tbody>
</table>

<h3>About VF</h3>
VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Altra, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. Tracing its roots to 1899, the company has evolved through many brand acquisitions and dispositions.
Having examined the options trading patterns of VF, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of VF</h3>
<ul>
<li>Trading volume stands at 4,583,956, with VFC's price up by 5.8%, positioned at $22.79.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 19 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for VF, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

VF Options Trading: A Deep Dive into Market Sentiment

Financial giants have made a conspicuous bearish move on Tesla. Our analysis of options history for Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) revealed 504 unusual trades.
Delving into the details, we found 38% of traders were bullish, while 44% showed bearish tendencies. Out of all the trades we spotted, 236 were puts, with a value of $27,601,967, and 268 were calls, valued at $16,051,866.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $100.0 and $890.0 for Tesla, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Tesla options trades today is 5062.4 with a total volume of 8,254,798.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Tesla's big money trades within a strike price range of $100.0 to $890.0 over the last 30 days.
<h3>Tesla Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736534723_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSLA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/10/25</td>
<td>$405.05</td>
<td>$403.45</td>
<td>$403.7</td>
<td>$800.00</td>
<td>$2.0M</td>
<td align="right">0</td>
<td align="right">50</td>
</tr>
<tr>
<td>TSLA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/10/25</td>
<td>$404.35</td>
<td>$401.95</td>
<td>$403.01</td>
<td>$800.00</td>
<td>$2.0M</td>
<td align="right">0</td>
<td align="right">250</td>
</tr>
<tr>
<td>TSLA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/10/25</td>
<td>$404.35</td>
<td>$401.95</td>
<td>$403.01</td>
<td>$800.00</td>
<td>$2.0M</td>
<td align="right">0</td>
<td align="right">150</td>
</tr>
<tr>
<td>TSLA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/10/25</td>
<td>$204.55</td>
<td>$202.3</td>
<td>$203.5</td>
<td>$600.00</td>
<td>$1.0M</td>
<td align="right">0</td>
<td align="right">50</td>
</tr>
<tr>
<td>TSLA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$180.8</td>
<td>$179.65</td>
<td>$180.27</td>
<td>$500.00</td>
<td>$162.2K</td>
<td align="right">480</td>
<td align="right">18</td>
</tr>
</tbody>
</table>

<h3>About Tesla</h3>
Tesla is a vertically integrated battery electric vehicle automaker and developer of autonomous driving software. The company has multiple vehicles in its fleet, which include luxury and midsize sedans, crossover SUVs, a light truck, and a semi truck. Tesla also plans to begin selling more affordable vehicles, a sports car, and a robotaxi. Global deliveries in 2024 were a little below 1.8 million vehicles. The company sells batteries for stationary storage for residential and commercial properties including utilities and solar panels and solar roofs for energy generation. Tesla also owns a fast-charging network.
<h3>Current Position of Tesla</h3>
<ul>
<li>Trading volume stands at 44,313,069, with TSLA's price up by 0.63%, positioned at $397.44.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 19 days.</li>
</ul>
<h3>Expert Opinions on Tesla</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $349.972.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Canaccord Genuity keeps a Buy rating on Tesla with a target price of $404. 
&#x2A; An analyst from Truist Securities has decided to maintain their Hold rating on Tesla, which currently sits at a price target of $351. 
&#x2A; An analyst from B of A Securities has revised its rating downward to Neutral, adjusting the price target to $490. 
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on Tesla, which currently sits at a price target of $480. 
&#x2A; An analyst from GLJ Research has revised its rating downward to Sell, adjusting the price target to $24. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Tesla, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Unpacking the Latest Options Trading Trends in Tesla

Chanson International Shares Halted On Circuit Breaker To The Downside, Stock Now Down -18.8%

Fashion company Capri Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) shares are trading higher on Friday. Italian luxury fashion brand Prada is said to be among the potential buyers exploring a bid for Versace, the renowned fashion group currently <a href="https://www.benzinga.com/25/01/42824409/sentiment-for-capri-holdings-has-turned-too-negative-this-analyst-notes-3-ways-to-win">up for sale by Capri.</a>
Prada is working with Citigroup Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) to assess the feasibility of a possible acquisition, according to a report from Reuters.
The move comes after the Federal Trade Commission has launched a lawsuit to halt <a href="https://www.benzinga.com/markets/equities/24/04/38382351/ftc-files-lawsuit-to-block-8-5b-merger-of-coach-and-versace-handbag-makers">the $8.5 billion acquisition</a> of Capri by Tapestry Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>). Both companies decided to mutually end their merger agreement, citing uncertainties in the legal process and the expectation that it would not be resolved by the <a href="https://www.benzinga.com/news/buybacks/24/11/41971497/tapestry-and-capri-call-off-8-5b-deal-amid-legal-hurdles">Feb. 10, 2025 deadline</a>.
Also Read: <a href="https://www.benzinga.com/25/01/42908403/macys-shuts-down-66-locations-to-boost-profitability">Macy&#8217;s Shuts Down 66 Locations As Part Of New Chapter Strategy</a>
Since then Capri has been exploring potential buyers for its Versace and Jimmy Choo brands and was said to have created a data room containing confidential details about the businesses for prospective buyers, with the goal of gauging interest <a href="https://www.benzinga.com/24/12/42513221/capri-holdings-stock-climbs-on-report-of-potential-sale-of-versace-jimmy-choo">before the holiday season</a>.
Capri is the parent company for fashion brands like Versace, Jimmy Choo, and Michael Kors.
The company reported a 16.4% decline in its second-quarter FY25 revenue with Versace&#8217;s decreasing 28.2%, impacted by softening global demand for <a href="https://www.capriholdings.com/news-releases/news-releases-details/2024/Capri-Holdings-Limited-Announces-Second-Quarter-Fiscal-2025-Results-b3d8ee77e/default.aspx">fashion luxury goods</a>.
Prada, on the other hand, posted a revenue of €3.829 billion for the nine months ending on <a href="https://www.pradagroup.com/content/dam/pradagroup/documents/investors/9M-2024/24.10.30_Prada_Group_Q3-24_Results_Press_Release.pdf" target="_blank" rel="noopener">Sep. 30, 2024, an 18% increase</a>.
Price Action: CPRI shares were up 9.5% at $23.56 at last check Friday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/42913319/beer-maker-constellation-brands-q3-sales-hit-by-subdued-spending-stock-slides">Beer Maker Constellation Brands&#8217; Q3 Sales Hit By Subdued Spending</a></li>
</ul>
Photo: Giorgio Borelli/Shutterstock.com

Movers

General

CPRI

Capri's Stock Rises As Prada Considers Potential Acquisition Of Versace

Relay Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 4.55%

Citigroup analyst Christopher Allen maintains Interactive Brokers Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) with a Buy and raises the price target from $180 to $220.

IBKR

Citigroup Maintains Buy on Interactive Brokers Gr, Raises Price Target to $220

Relay Therapeutics Shares Resume Trade Following Circuit Breaker Halt

Citigroup analyst Christopher Allen maintains LPL Finl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) with a Buy and raises the price target from $310 to $385.

LPLA

Citigroup Maintains Buy on LPL Finl Hldgs, Raises Price Target to $385

On Friday, Dyne Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) revealed new data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42908297/dyne-therapeutics-reports-new-clinical-data-showing-compelling-impact-on-multiple-measures-of-myot" rel="noreferrer noopener">myotonic dystrophy type 1 (DM1)</a>.
Dyne plans to begin a global Registrational Expansion Cohort with the potential to support a submission for U.S. Accelerated Approval based on biomarker and functional data in H1 2026.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40692261/muscle-disease-drug-developer-dyne-therapeutics-stock-plunges-after-updated-data-from-duchenne-mu" rel="noreferrer noopener">Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy</a>
Dyne reported efficacy data from adult DM1 patients enrolled in the randomized, placebo-controlled MAD portion of the DYNE-101 ACHIEVE trial, including data from the 6.8 mg/kg Q8W cohort (n=8) at up to 6 months.
At the 6.8 mg/kg Q8W dose, DYNE-101 resulted in significant splicing correction at 3 months compared to baseline, which was associated with progress in multiple functional endpoints, beginning at 3 months and continuing at 6 months.
<ul>
<li>Analysis of muscle biopsy data for the 6.8 mg/kg Q8W cohort showed a substantial knockdown of Drug Metabolism and Pharmacokinetics (DMPK) (DYNE-101 molecular target) RNA levels. Splicing correction at 3 months for the 6.8 mg/kg Q8W cohort was robust. It was associated with improvement in multiple functional endpoints, supporting CASI-22 at 3 months as a surrogate endpoint for potential U.S. Accelerated Approval.</li>
<li>Early and sustained improvement in myotonia as measured by video hand opening time (vHOT) was seen in the 6.8 mg/kg Q8W cohort and at low doses with modest splicing correction, deepening with more time on the drug.</li>
<li>Functional measures showed early and sustained clinical benefit at the 6.8 mg/kg Q8W dose.</li>
</ul>
Dyne also reported safety and tolerability data from 56 patients. Most of the treatment-emergent adverse events were mild or moderate, and no related serious treatment-emergent adverse events have been identified.
Based on previous dialogue with the FDA&#8217;s Center for Drug Evaluation and Research division, Dyne continues to pursue accelerated approval in the U.S. based on splicing as a surrogate endpoint.
Dyne anticipates completing enrollment in the Registrational Expansion Cohort in mid-2025 and submitting for U.S. Accelerated Approval in H1 2026.
Price Action: DYN stock is down 35.3% at $14.91 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42915528/td-synnex-shares-delivers-earnings-beat-and-boosts-dividend-by-10" target="_blank" rel="noreferrer noopener">TD SYNNEX Delivers Strong Q4, Raises Dividend Amid IT Growth Momentum; Stock Gains</a></li>
</ul>
Image via Shutterstock.

Biotech

Equities

Health Care

Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?

Citigroup analyst Christopher Allen maintains Raymond James Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>) with a Neutral and raises the price target from $145 to $170.

Comments

CLAL INSURANCE ENTERPRISE by CLAL INSURANCE ENTERPRISES HOLDINGS LTD.

News

Latest news for CLAL INSURANCE ENTERPRISE by CLAL INSURANCE ENTERPRISES HOLDINGS LTD. (OTC:CIEHF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga